Brief: Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)
04/12/2025 13:17
Dec 4 (Reuters) - Heron Therapeutics Inc HRTX.O: HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV) Source text: ID:nGNX2zrgwS Further company coverage: HRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heron Therapeutics
See all newsHeron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Heron Therapeutics Inc expected to post earnings of 1 cent a share - Earnings Preview
Brief: U.S. District Court Issues Decision Regarding CINVANTI Patents
Heron Therapeutics' Q1 revenue falls as oncology sales drop